Arecor Therapeutics (LON:AREC) Posts Quarterly Earnings Results

Arecor Therapeutics (LON:AREC) posted its quarterly earnings data on Thursday. The company reported GBX (8) EPS for the quarter, Digital Look Earnings reports. Arecor Therapeutics had a net margin of 38.74% and a return on equity of 14.26%.

Arecor Therapeutics Trading Down 3.0%

AREC stock traded down GBX 2.19 during trading on Friday, reaching GBX 70.31. 46,696 shares of the stock were exchanged, compared to its average volume of 24,785. The company has a current ratio of 4.35, a quick ratio of 6.24 and a debt-to-equity ratio of 1.52. The firm has a market capitalization of £26.55 million, a price-to-earnings ratio of 35.16 and a beta of -0.18. The business has a 50 day moving average price of GBX 71.87 and a 200-day moving average price of GBX 67.97. Arecor Therapeutics has a 1 year low of GBX 56 and a 1 year high of GBX 95.

About Arecor Therapeutics

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.